Foresee Pharmaceuticals Co., Ltd. received the approval letter of New Drug Application of CAMCEVI 42 mg from Taiwan Ministry of Health and Welfare on August 17, 2023. The approved product name is CAMCEVI (Leuprolide) injectionable emulsion, 42 mg, indicated for the palliative care of advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. The company has submitted document as per the request by the Ministry of Health and Welfare, and has obtained the official pharmaceutical license on December 1, 2023.

As the population grows and gradually ages, prostate cancer patients have grown in number. According to Nova One Advisor, the global prostate cancer therapeutics market was worth about USD 15.2 billion in 2021. By estimation, the global prostate cancer drug market value will grow to USD 24.9 billion in 2030, with a CAGR of 9.4%.

According to Precision Reports data, the global market value of leuprolide was approximately USD 2.455 billion (all indications included) in 2021. By estimation, the market value will grow to USD 3.264 billion in 2027, with a CAGR of 4.86%. Designed and developed through Foresee's pioneering Stabilized Injectable Formulation technologies, CAMCEVI 42 mg is a differentiated ready-to-use 6-month depot injection, which overcomes the requirement of manual reconstitution ?

an obstacle that the already marketed leuprolide products face that can lead to handling inconvenience and potential risks of handing errors.